HIV Vaccine Awareness Day: Thinking Key and Vulnerable Populations 

HIV Vaccine Awareness Day: Thinking Key and Vulnerable Populations   

To commemorate the 2018 HIV Vaccine Awareness Day which is marked May 18th every year, a group, Heartland Alliance International Nigeria (HAI), made a statement. POSTERITY MEDIA, in partnership with New HIV Vaccine and Microbicide Advocacy Society (NHVMAS) to commemorate the day, brings you the full statement as released: 

Press release from Heartland Alliance International Nigeria

Heartland Alliance International Nigeria (HAI) joins The New HIV Vaccine and Microbicide Advocacy Society (NHVMAS) and the world to commemorate the 20th anniversary of the HIV Vaccine Awareness Day (HVAD).

May 18 is HIV Vaccine Awareness Day—an opportunity to recognize the volunteers, community members, health professionals, and scientists involved in HIV vaccine research. It is also a time to educate about the importance of HIV vaccine research and urge the international community to recognize the importance of investing in new technologies as a critical element of a comprehensive response to the HIV/AIDS epidemic.

HAI works at the forefront of HIV prevention, treatment and care for key and vulnerable populations in Nigeria. With a national HIV prevalence rate of 3.17%, key populations are disproportionately affected, with men who have sex with men, female sex workers and people who inject drugs having prevalence rates of 22.9%, 19.4% and 3.4% respectively. Despite the increased use of treatment and prevention options, this on its own is unlikely to stop the HIV epidemic. As Bill Clinton rightly stated, “only a truly effective, preventive HIV vaccine can limit and eventually eliminate the threat of AIDS.”

As an organization committed to securing the rights and well-being of marginalized people and communities, we are committed on this day and indeed every day to international research that will one day end the AIDS epidemic. We therefore join hands with other HIV vaccine advocates to promote the continued urgent need for a vaccine to prevent HIV infection and AIDS.

This press release opens up the NHVMAS festival of blogs, which calls on all persons to share blogs on the NHVMAS website celebrating HIV vaccine research efforts until date, and sharing visions of what impact a HIV vaccine can have on global health, peace and development. The objective of this festival of blogs is to amplify all voices about their interest in HIV vaccine development, their expectations about the vaccine, and promote continued investment and HIV vaccine research.

Keep up with NHVMAS activities on our social media platforms and join the conversation

Facebook: www.facebook.com/nhvmas

Twitter: @nhv_mas

PATA: FG must provide support, enabling environment for HIV vaccine research

 

May 18 is observed as HIV Vaccine Awareness Day globally. As we join the international community to mark this day in Nigeria Positive Action for Treatment Access (PATA), recognizes and thank all the volunteers, community members, health professionals, civil society advocates and scientists involved in HIV vaccine research

This day also presents a unique opportunity to educate communities about the importance of HIV vaccine research.

No doubt there has been much progress in HIV/AIDS research globally. Antiretroviral therapies have contributed to longer and healthier lives for people living with HIV. Pre- exposure prophylaxis has helped to reduce the risk of HIV infection by those not living with HIV.

While these and other preventive tools have the power to reduce the incidence of HIV infection, a safe and effective vaccine would even yield better outcomes. A vaccine would drastically reduce the number of people who become infected and contribute immensely to the global target of ending the AIDS epidemic by 2030.

As effort towards HIV vaccine intensifies in Nigeria, attention should be given to the following:

  • Government at all levels (local, state and federal), should put in place adequate structures and enabling environment to promote vaccine research and development.
  •  Intensive training and retraining of local personnel especially scientists and researchers and exposure to global best practices.
  • Continue on going prevention efforts to reduce new infections, and intensify treatment, care and support services for those infected, while keeping the search for vaccine in focus.
  • Aggressively promote local content in the search for vaccine. The  resolution at the 4th National Council recently held in Abuja, March 19-20, 2018 (Resolution 6:Council approved that the local manufacture of Anti-retroviral (ARV) drugs, Rapid Test Kits (RTKs) and other HIV-related commodities be encouraged (NCA/04/19B) is indeed the way to go with the vaccine initiative in Nigeria.
  • Need for intensive partnership between funders, scientists, advocates and community stakeholders.
  • Community engagement should be given top priority at all stages of the vaccine research and development process.
  • Ensuring ethical standards in trials to ensure we have a vaccine that is “safe, effective, durable, affordable, and accessible.”
  • Mobilization of resources to ensure that the vaccine, when available, gets to the people who need it.
  • Active engagement of people living with HIV and civil society advocates in the research and development process.
  • Massive sensitization as a strategy to address issues of stigma and discrimination. Partnership with the media for effective awareness creation is most desirable.

Keep up with NHVMAS activities on our social media platforms and join the conversation

Facebook: www.facebook.com/nhvmas

Twitter: @nhv_mas

HVAD: NIMR urges Nigerians to support HIV vaccine research

HVAD: NIMR urges Nigerians to support HIV vaccine research

HVAD: NIMR urges Nigerians to support HIV vaccine research

THE NIGERIA INSTITUTE OF MEDICAL RESEARCH INVESTED IN DEVELOPMENT OF A HIV VACCINE RESPONSIVE TO THE CIRCULATING HIV STRAIN IN NIGERIA

Image result for salako NIMR

On the 18th of    May,    2018 HIV vaccine advocates in many countries around the globe will be commemorating the HIV Vaccine Awareness Day. The concept of Global HIV Vaccine Awareness Day emerged from the May 18, 1997 inauguration speech made by then-President William Jefferson Clinton at Morgan State University. He challenged the world to set new goals in the emerging age of science and technology and develop a HIV vaccine within the next decade. Since then, the advocates and communities around the world has commemorated this day with activities to raise awareness about HIV vaccine.

Today, the Nigerian Institute of Medical Research Lagos happily joins the global community to celebrate the almost four decades of investment of researchers, research volunteers, community members, health professionals, funders in developing a HIV vaccine. Tremendous progress has been made and we remain hopeful a HIV vaccine will be developed.

We join HIV vaccine advocates to urge the international community to continue to recognize the importance of investing in new technologies as a critical element of a comprehensive response to the HIV and AIDS epidemic. We further call on Nigeria and Nigerians to recognize, support and invest not only in HIV vaccine research but research in general.

The race to developing a HIV vaccine is a marathon race. Slow and steady but assuredly that the end will be sooner than later. It requires investment, hard work, and the non-stop commitment towards a goal. The race requires countries around the world to invest in research that makes it feasible for its citizens to benefit from the global research.

Nigeria is committed to joining forces to ensure we not only develop a HIV vaccine, but ensure we address barriers and challenges to its access when developed. As always, we shall lead the policy formulation landscape, offer relevant trainings and speak up as advocates for access to the finished product. We are committed to ensuring Nigeria is not left behind in the race to end the HIV and AIDS epidemic.

Researchers in NIMR are aware that the strain of the HIV virus that circulates in Nigeria is quite distinct from other strain circulating elsewhere. It is the least responsive to VRC01. For this reason, the institute is watching the field as it evolves so it acts responsibly for the care of Nigerians.

NIMR Lagos is a house hold name in the fight against HIV epidemic. Since 2002, we have not only provided comprehensive HIV care treatment and support to over 24,000 Nigerians adult, pregnant women and children, but have also set the pace in innovative care delivery. In recent times, we have sought for collaboration with leading HIV research institutions in Africa to improve our research outcomes, including research for a HIV vaccine highly sensitive to the Nigerian HIV strain.

We are committed to providing an enabling environment and opportunities for HIV vaccine research in Nigeria. We look forward to new partnerships and collaborations to advance the global agenda to develop a HIV vaccine accessible to all in the shortest possible time.

 

Professor Babatunde Lawal Salako MD, FWCP, FRCP

Director General

 

Keep up with NHVMAS activities on our social media platforms and join the conversation

Facebook: www.facebook.com/nhvmas

Twitter: @nhv_mas

HVAD: NACA urges collaborative, focused action on HIV vaccine

HVAD: NACA urges collaborative, focused action on HIV vaccine

HVAD: NACA urges collaborative, focused action on HIV vaccine

NACA PRESS STATEMENT

Image result for saliu naca boss

Today marks the 21st anniversary of global efforts to develop a HIV vaccine. Although progress in HIV vaccine development by the scientific community continues to raise hope that one day this feat will be achieved, a lot of work is still required.

The HIV Vaccine Awareness Day is a day that recognizes stakeholders involved in HIV vaccine research, including health professionals, volunteers, members of the civil society and scientists. It provides an opportunity to educate communities about the importance of developing a HIV vaccine for both preventive and treatment purposes.

Over 3 million people in Nigeria are living with HIV. Every new infection has social and economic consequences for the country. A successful HIV vaccine would reduce the number of new infections and also slow the progress of the illness in those infected with the virus. It is important for all stakeholders to double their efforts to ensure that Nigeria as a country contributes positively to the development of a HIV vaccine.

The Director General of the National Agency for the Control of AIDS (NACA), Dr Sani Aliyu, is optimistic that developing a HIV vaccine is feasible in the not-too-distant future, and calls for renewed commitment by all stakeholders to make this feat happen. ‘’ As we mark World HIV Vaccine Day, I call for a renewed commitment from all stakeholders to push for the realization of the production of this much needed vaccine’’

The established roadmap for HIV vaccine development is vigorously being followed, with stakeholders conducting operational and implementation research to address potential barriers that can hinder access to HIV Vaccines. NACA, in partnership with the New HIV Vaccine and Microbicide Advocacy Society (NHVMAS) will continue to collaborate with relevant stakeholders in promoting community education and awareness as well as intensify efforts to ensure that an effective HIV vaccine is developed to arrest the HIV epidemic at a global level.

Keep up with NHVMAS activities on our social media platforms and join the conversation

Facebook: www.facebook.com/nhvmas

Twitter: @nhv_mas

Accelerating the era of HIV vaccination by Linda-Gail Bekker

Accelerating the era of HIV vaccination by Linda-Gail Bekker

Accelerating the era of HIV vaccination by Linda-Gail Bekker

By Linda-Gail Bekker, International AIDS Society President

Vaccines are modern miracles. Every year, vaccines save up to 3 million lives worldwide [[1]]. The measles vaccine alone has saved more than 20 million lives since 2000 [[2]]. Smallpox, a disease that as recently as the 1960s was associated with a death toll comparable to HIV, has now been eradicated as a result of vaccination efforts. Immunization programmes are on the cusp of eliminating polio, and expanded use of the hepatitis B vaccine is contributing to reductions in the global burden of that disease as well [[3]].

In the case of HIV, no preventive vaccine is currently available. But we have come a very long way in the search for an HIV vaccine, with a rich research and development pipeline that now includes an array of approaches to HIV immunization.

My own involvement in HIV vaccine research began in 2004 when we did the first community-based “willingness to participate” studies. Gratifyingly, we discovered that communities in South Africa believe in vaccines and have great hope for an effective HIV vaccine. Although the earliest vaccine research did not yield an effective vaccine, these efforts left us with lessons and insights that have proven invaluable in the search for an effective vaccine.

Indeed, there are signs that we might soon see a light at the end of the tunnel. In 2009, a clinical trial in Thailand confirmed for the first time that a vaccine could prevent HIV infection. Currently, I am serving as Co-Chair of HVTN 072 together with Dr Glenda Grey (Chair); this is a large efficacy trial in South Africa of a vaccine that is evaluating what we hope is an improved version of the vaccine tested in the Thai trial. One of my sites is also involved in one of a series of studies evaluating whether intravenous infusions of HIV antibodies can protect against HIV acquisition.

In my many years of HIV vaccine research, I’ve learned a lot about what makes a successful vaccine trial. In particular, community engagement and support is an essential building block for successful research. In South Africa, communities are thirsting for an HIV vaccine and are ready to put to use a vaccine proven to be safe and effective. Given the grassroots enthusiasm for new methods to prevent HIV infection, people are eager to enrol in vaccine research in South Africa. And communities have actively stepped forward to promote and support these HIV prevention trials.

The worst possible outcome for a large, expensive Phase III efficacy trial is a set of results that are ambiguous, unclear or difficult to interpret. That’s why such care and thought goes into the design and roll out of a Phase III trial. The past several years have seen an exciting expansion of HIV prevention options, but this has paradoxically made vaccine trials more difficult to design. Our studies offer all participants access to PrEP – an ethical imperative, but one that complicates efforts to compare the experimental vaccine arm of the trial with a control group. This means that innovation in the design of new trials will be critical as we move forward in our search for an effective HIV vaccine.

For those of us who have witnessed the highs and lows of our quest for a preventive vaccine, these are exciting times. But we aren’t there yet, and there is a real risk that long-term commitment to finding a vaccine could wither over time. We must not allow that to happen, as a preventive vaccine will likely be essential for ending the HIV epidemic once and for all.

It is our hope that through the recently announced partnership between the International AIDS Society (IAS) and the Global HIV Vaccine Enterprise, we will foster new collaborations between the HIV vaccine community and the broader HIV community to work towards our common goal of accelerating the era of HIV vaccination.

Not that long ago, many leading scientific experts questioned whether a vaccine against HIV was even feasible. We now know that the potential for HIV vaccination is real. We must now redouble our efforts and be smart in our choices, so that we reach the ultimate finish line in our fight against HIV.

1http://www.who.int/en/news-room/fact-sheets/detail/immunization-coverage.

https://www.cdc.gov/mmwr/volumes/65/wr/mm6544a6.htm.

https://www.thelancet.com/journals/langas/article/PIIS2468-1253(18)30056-6/fulltext

Keep up with NHVMAS activities on our social media platforms and join the conversation

Facebook: www.facebook.com/nhvmas

Twitter: @nhv_mas